Basal cell carcinoma - I-Basal Cell Carcinoma
☆ Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Izilonda ezibuhlungu ezichaphazela ulusu lwempumlo kumntu owalupheleyo zihlala zifunyaniswa njenge I-Basal Cell Carcinoma (Basal cell carcinoma). Impumlo yindawo eqhelekileyo yokwenzeka kolu hlobo lomhlaza wolusu.
I-Basal Cell Carcinoma (Basal cell carcinoma) inokuba nemida engaqhelekanga kunye nezilonda.
I-Basal Cell Carcinoma (Basal cell carcinoma) inokubhidaniswa nentsumpa.
References
Basal cell carcinoma (BCC) lolona hlobo luxhaphakileyo lomhlaza wolusu. Ukukhanya kwelanga ngoyena nobangela. Phantse zonke iimeko ze-BCC zibonisa umqondiso we-Hedgehog ogqithiseleyo kuhlalutyo lwe-molecular. Unyango olwahlukeneyo luyafumaneka kwaye lukhethwa ngokusekelwe kumngcipheko wokuphinda, ukubaluleka kokugcinwa kwezicubu, ukhetho lwesigulane, kunye nobungakanani besifo.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas lolona hlobo luxhaphakileyo lomhlaza wolusu kubantu abadala abanolusu olusulungekileyo abaneminyaka engama-50 nangaphezulu. Amanani azo aye enyuka ehlabathini lonke, ingakumbi ngenxa yokuchanabeka elangeni. Iimeko ezithile zofuzo zinokwenza abantu batyekele ekuphuhliseni ezi zomhlaza besebancinci. Basal cell carcinomas ziyohluka ngokobungqongqo, ukusuka kwizilonda ezingaphezulu okanye ezinokuthi zinyangeke ngokulula ukuya kwezona zininzi zifuna ingxoxo kumaqela ezonyango awodwa. Iprognosis ixhomekeke kumathuba okuba umhlaza ubuye okanye amandla awo okonakalisa izicubu ezikufutshane. Utyando lolona nyango lusemgangathweni kwiimeko ezininzi, ukuqinisekisa ukususwa okuchanekileyo kunye namathuba aphantsi okuphinda. Iindlela ezincinci ezihlaselayo zinokunyanga ngokufanelekileyo izilonda ezingaphezulu.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Olona nyango luphambili lwe-BCC lutyando. Ngomngcipheko ophezulu okanye i-BCC ephindaphindiweyo, ngokukodwa kwiindawo ezibalulekileyo, utyando olulawulwa yi-micrographically lunconywa. Izigulana ezinomngcipheko osezantsi ongeyomfuneko we-BCC zisenokuthathela ingqalelo unyango olusentloko okanye iindlela ezonakalisayo. Unyango lwe-Photodynamic lusebenza kakuhle kwii-BCC ze-nodular ezinomngcipheko ophezulu kunye nomngcipheko ophantsi. Kwi-BCC ekwinqanaba eliphezulu okanye yemetastatic, iHedgehog inhibitors (vismodegib, sonidegib) iyacetyiswa. Ukuba kukho ukuqhubela phambili kwesifo okanye ukunganyamezeli kwi-Hedgehog inhibitors, unyango lwe-immunotherapy nge anti-PD1 antibody (cemiplimab) lunokuqwalaselwa. Unyango ngerediyo lukhetho olulungileyo kwizigulana ezingakwaziyo ukwenza utyando, ingakumbi izigulana ezindala. I-Electrochemotherapy inokuqwalaselwa ukuba utyando okanye i-radiotherapy ayiyokhetho.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
Izinto ezinobungozi zibandakanya ukuvezwa kokukhanya kwe-ultraviolet, unyango lwe-radiation, ukubonakaliswa kwexesha elide kwi-arsenic kunye nokusebenza kakubi kwe-immune system (umz. Ukutshintshwa kwamalungu). Ukutyhileka kwizibane zeUV ngexesha lobuntwana kuyingozi kakhulu.
Emva kokuxilongwa nge-biopsy, unyango ludla ngokususwa ngotyando. Oku kunokuba ngokusikwa okulula ukuba umhlaza umncinci; Ukuba umhlaza awumncinci, utyando lwe-Mohs luyacetyiswa ngokubanzi.
I-Basal cell carcinoma ithatha i-32% yeepesenti zabo bonke umhlaza kwihlabathi jikelele. Kwimihlaza yolusu ngaphandle kwemelanoma, malunga ne-80% yomhlaza we-basal-cell. EUnited States, malunga ne-35% yamadoda amhlophe kunye nama-25% amabhinqa amhlophe achatshazelwa yi-basal cell carcinoma ngaxa lithile ebomini bawo.
○ Uxilongo kunye noNyango
#Dermoscopy
#Skin biopsy
#Mohs surgery